Tall height and obesity are associated with an increased risk of aggressive prostate cancer: results from the EPIC cohort study

BMC Medicine

Research Article

Maria-Dolores Chirlaque¹  Elena Molina-Portillo²  Aurelio Barricarte³  Paul N. Appleby⁴  Ruth C. Travis⁴  Aurora Perez-Cornago⁴  Julie A. Schmidt⁴  Timothy J. Key⁴  Rosario Tumino⁵  Domenico Palli⁶  Anja Olsen⁷  Anne Tjønneland⁷  Elio Riboli⁸  Dagfinn Aune⁸  Heather Ward⁸  H. Bas Bueno-de-Mesquita⁹  Heiner Boeing^1,10  Annika Steffen^1,10  Konstantinos K. Tsilidis^1,11  Kim Overvad^1,12  Christel Häggström^1,13  Pär Stattin^1,14  Rudolf Kaaks^1,15  Tilman Kühn^1,15  Vittorio Krogh^1,16  Maria Kritikou^1,17  Antonia Trichopoulou^1,18  Pagona Lagiou^1,19  Nick Wareham^2,20  Tobias Pischon^2,21  J. Ramón Quirós^2,22  Nerea Larrañaga^2,23  Marc Gunter^2,24  Heinz Freisling^2,24  Carlotta Sacerdote^2,25  Antonio Agudo^2,26  Kay-Tee Khaw^2,27 

[1] CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain;Department of Epidemiology, Regional Health Council, IMIB-Arrixaca, Murcia, Spain;Department of Health and Social Sciences, Universidad de Murcia, Murcia, Spain;CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain;Escuela Andaluza de Salud Pública, Instituto de Investigación Biosanitaria ibs, GRANADA, Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain;CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain;Navarra Public Health Institute, Pamplona, Spain;Navarra Institute for Health Research (IdiSNA), Pamplona, Spain;Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, OX3 7LF, Oxford, United Kingdom;Cancer Registry and Histopathology Unit, “Civic - M.P. Arezzo” Hospital, Azienda Sanitaria Provinciale, Ragusa, Italy;Cancer Risk Factors and Life-Style Epidemiology Unit, Cancer Research and Prevention Institute – ISPO, Florence, Italy;Danish Cancer Society Research Center, Copenhagen, Denmark;Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom;Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom;Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands;Department of Social & Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia;Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbrücke, Nuthetal, Germany;Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece;Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom;Department of Public Health, Section for Epidemiology, Aarhus University, Aarhus, Denmark;Department of Surgical Sciences, Uppsala University, Uppsala, Sweden;Department of Biobank Research, Umeå University, Umeå, Sweden;Department of Surgical Sciences, Uppsala University, Uppsala, Sweden;Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden;Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany;Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy;Hellenic Health Foundation, Athens, Greece;Hellenic Health Foundation, Athens, Greece;WHO Collaborating Center for Nutrition and Health, Unit of Nutritional Epidemiology and Nutrition in Public Health, Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Athens, Greece;Hellenic Health Foundation, Athens, Greece;WHO Collaborating Center for Nutrition and Health, Unit of Nutritional Epidemiology and Nutrition in Public Health, Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Athens, Greece;Department of Epidemiology, Harvard School of Public Health, Boston, USA;MRC Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom;Molecular Epidemiology Group, Max Delbrueck Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany;Public Health Directorate, Asturias, Spain;Public Health Division of Gipuzkoa, Regional Government of the Basque Country, Donostia, Spain;CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain;Section of Nutrition and Metabolism, International Agency for Research on Cancer, Lyon, France;Unit of Cancer Epidemiology, AO Citta’ della Salute e della Scienza-University of Turin and Center for Cancer Prevention (CPO-Piemonte), Turin, Italy;Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology-IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain;University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom;

关键词: Adiposity;    Obesity;    Height;    Prostate cancer;    Cohort study;    Tumour characteristics;    High grade;   

DOI  :  10.1186/s12916-017-0876-7

 received in 2016-12-08, accepted in 2017-05-16,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundThe relationship between body size and prostate cancer risk, and in particular risk by tumour characteristics, is not clear because most studies have not differentiated between high-grade or advanced stage tumours, but rather have assessed risk with a combined category of aggressive disease. We investigated the association of height and adiposity with incidence of and death from prostate cancer in 141,896 men in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort.MethodsMultivariable-adjusted Cox proportional hazards models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). After an average of 13.9 years of follow-up, there were 7024 incident prostate cancers and 934 prostate cancer deaths.ResultsHeight was not associated with total prostate cancer risk. Subgroup analyses showed heterogeneity in the association with height by tumour grade (Pheterogeneity = 0.002), with a positive association with risk for high-grade but not low-intermediate-grade disease (HR for high-grade disease tallest versus shortest fifth of height, 1.54; 95% CI, 1.18–2.03). Greater height was also associated with a higher risk for prostate cancer death (HR = 1.43, 1.14–1.80). Body mass index (BMI) was significantly inversely associated with total prostate cancer, but there was evidence of heterogeneity by tumour grade (Pheterogeneity = 0.01; HR = 0.89, 0.79–0.99 for low-intermediate grade and HR = 1.32, 1.01–1.72 for high-grade prostate cancer) and stage (Pheterogeneity = 0.01; HR = 0.86, 0.75–0.99 for localised stage and HR = 1.11, 0.92–1.33 for advanced stage). BMI was positively associated with prostate cancer death (HR = 1.35, 1.09–1.68). The results for waist circumference were generally similar to those for BMI, but the associations were slightly stronger for high-grade (HR = 1.43, 1.07–1.92) and fatal prostate cancer (HR = 1.55, 1.23–1.96).ConclusionsThe findings from this large prospective study show that men who are taller and who have greater adiposity have an elevated risk of high-grade prostate cancer and prostate cancer death.

【 授权许可】

CC BY   
© The Author(s). 2017